Literature DB >> 33778703

Performance of the Vancouver Risk Calculator Compared with Lung-RADS in an Urban, Diverse Clinical Lung Cancer Screening Cohort.

Abraham Kessler1, Robert Peng1, Edward Mardakhaev1, Linda B Haramati1, Charles S White1.   

Abstract

Purpose: To compare the performance of the Vancouver risk calculator (VRC) with the American College of Radiology's Lung CT Screening Reporting and Data System (Lung-RADS) for a lung cancer screening cohort in an urban, diverse clinical setting. Materials and
Methods: This study included a total of 486 patients with lung nodules (63 years ± 5.2 [standard deviation], 261 female patients), 448 of whom had lung nodules that were subsequently classified as benign and 38 of whom had those that were classified as malignant. The mean follow-up time was 40.0 months ± 14. Institutional review board approval was obtained for this Health Insurance Portability and Accountability Act-compliant retrospective study, and a waiver of informed consent was received. All patients undergoing lung cancer screening who underwent an initial baseline screening CT between December 2012 and June 2016 that demonstrated a nodule and had at least 1 year of follow-up comprised the study population. Each examination was assigned a Lung-RADS score between 2 and 4B, with 4A and 4B considered as showing positive results. The VRC calculates the risk of cancer at different thresholds using nine variables related to patient and imaging characteristics. Analysis was performed per patient based on the largest nodule. Lung-RADS and VRC using the 5% threshold were compared to assess diagnostic performance in determining the risk of developing lung cancer in a patient with a nodule found at screening CT. The McNemar test was used to compare differences in performance between Lung-RADS and VRC.
Results: Lung-RADS resulted in nine false-positive and 16 false-negative findings, whereas VRC with a 5% threshold resulted in 29 false-positive and 10 false-negative findings. Overall sensitivity and specificity for Lung-RADS was 58.0% and 98.0%, and for VRC with a 5% threshold was 73.7% and 93.5%, respectively (P = .313, P < .001, respectively).
Conclusion: The VRC performs well in an urban, diverse lung cancer screening program. Further studies may be directed at determining whether its use in conjunction with Lung-RADS leads to improved lung cancer detection.Keywords: CT, Lung, Thorax© RSNA, 2020. 2020 by the Radiological Society of North America, Inc.

Entities:  

Year:  2020        PMID: 33778703      PMCID: PMC7983652          DOI: 10.1148/rycan.2020190021

Source DB:  PubMed          Journal:  Radiol Imaging Cancer        ISSN: 2638-616X


  12 in total

1.  Volumetric computed tomography screening for lung cancer: three rounds of the NELSON trial.

Authors:  Nanda Horeweg; Carlijn M van der Aalst; Rozemarijn Vliegenthart; Yingru Zhao; Xueqian Xie; Ernst Th Scholten; Willem Mali; Erik Thunnissen; Carla Weenink; Harry J M Groen; Jan-Willem J Lammers; Kristiaan Nackaerts; Joost van Rosmalen; Matthijs Oudkerk; Harry J de Koning
Journal:  Eur Respir J       Date:  2013-07-11       Impact factor: 16.671

2.  Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017.

Authors:  Heber MacMahon; David P Naidich; Jin Mo Goo; Kyung Soo Lee; Ann N C Leung; John R Mayo; Atul C Mehta; Yoshiharu Ohno; Charles A Powell; Mathias Prokop; Geoffrey D Rubin; Cornelia M Schaefer-Prokop; William D Travis; Paul E Van Schil; Alexander A Bankier
Journal:  Radiology       Date:  2017-02-23       Impact factor: 11.105

3.  The Vancouver Lung Cancer Risk Prediction Model: Assessment by Using a Subset of the National Lung Screening Trial Cohort.

Authors:  Charles S White; Ekta Dharaiya; Erin Campbell; Lilla Boroczky
Journal:  Radiology       Date:  2016-10-13       Impact factor: 11.105

4.  Probability of cancer in pulmonary nodules detected on first screening CT.

Authors:  Annette McWilliams; Martin C Tammemagi; John R Mayo; Heidi Roberts; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; Simon Martel; Francis Laberge; Michel Gingras; Sukhinder Atkar-Khattra; Christine D Berg; Ken Evans; Richard Finley; John Yee; John English; Paola Nasute; John Goffin; Serge Puksa; Lori Stewart; Scott Tsai; Michael R Johnston; Daria Manos; Garth Nicholas; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Alain Tremblay; Paul Burrowes; Paul MacEachern; Rick Bhatia; Ming-Sound Tsao; Stephen Lam
Journal:  N Engl J Med       Date:  2013-09-05       Impact factor: 91.245

5.  Reduced lung-cancer mortality with low-dose computed tomographic screening.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; William C Black; Jonathan D Clapp; Richard M Fagerstrom; Ilana F Gareen; Constantine Gatsonis; Pamela M Marcus; JoRean D Sicks
Journal:  N Engl J Med       Date:  2011-06-29       Impact factor: 91.245

6.  Effectiveness of Lung-RADS in Reducing False-Positive Results in a Diverse, Underserved, Urban Lung Cancer Screening Cohort.

Authors:  Mark Kaminetzky; Hannah S Milch; Anna Shmukler; Abraham Kessler; Robert Peng; Edward Mardakhaev; Eran Y Bellin; Jeffrey M Levsky; Linda B Haramati
Journal:  J Am Coll Radiol       Date:  2018-08-23       Impact factor: 5.532

7.  Baseline characteristics of participants in the randomized national lung screening trial.

Authors:  Denise R Aberle; Amanda M Adams; Christine D Berg; Jonathan D Clapp; Kathy L Clingan; Ilana F Gareen; David A Lynch; Pamela M Marcus; Paul F Pinsky
Journal:  J Natl Cancer Inst       Date:  2010-11-22       Impact factor: 13.506

8.  Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.

Authors:  Martin C Tammemagi; Heidi Schmidt; Simon Martel; Annette McWilliams; John R Goffin; Michael R Johnston; Garth Nicholas; Alain Tremblay; Rick Bhatia; Geoffrey Liu; Kam Soghrati; Kazuhiro Yasufuku; David M Hwang; Francis Laberge; Michel Gingras; Sergio Pasian; Christian Couture; John R Mayo; Paola V Nasute Fauerbach; Sukhinder Atkar-Khattra; Stuart J Peacock; Sonya Cressman; Diana Ionescu; John C English; Richard J Finley; John Yee; Serge Puksa; Lori Stewart; Scott Tsai; Ehsan Haider; Colm Boylan; Jean-Claude Cutz; Daria Manos; Zhaolin Xu; Glenwood D Goss; Jean M Seely; Kayvan Amjadi; Harmanjatinder S Sekhon; Paul Burrowes; Paul MacEachern; Stefan Urbanski; Don D Sin; Wan C Tan; Natasha B Leighl; Frances A Shepherd; William K Evans; Ming-Sound Tsao; Stephen Lam
Journal:  Lancet Oncol       Date:  2017-10-18       Impact factor: 41.316

9.  Vancouver Risk Calculator Compared with ACR Lung-RADS in Predicting Malignancy: Analysis of the National Lung Screening Trial.

Authors:  Charles S White; Ekta Dharaiya; Sandeep Dalal; Rong Chen; Linda B Haramati
Journal:  Radiology       Date:  2019-01-22       Impact factor: 11.105

10.  Malignancy risk estimation of screen-detected nodules at baseline CT: comparison of the PanCan model, Lung-RADS and NCCN guidelines.

Authors:  Sarah J van Riel; Francesco Ciompi; Colin Jacobs; Mathilde M Winkler Wille; Ernst Th Scholten; Matiullah Naqibullah; Stephen Lam; Mathias Prokop; Cornelia Schaefer-Prokop; Bram van Ginneken
Journal:  Eur Radiol       Date:  2017-03-14       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.